This review highlights the importance of regulatory science, internationalization, and industry-academia-government collaboration to optimize aspirin-based antiplatelet therapy while balancing ischemic benefits and bleeding risks.
Supports cautious aspirin optimization amid bleeding risks; leaves open prospective trials on collaborative regulatory frameworks.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kazuhiro Sase (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: